PMID- 20457352
OWN - NLM
STAT- MEDLINE
DCOM- 20100524
LR  - 20211020
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Print)
IS  - 0360-3016 (Linking)
VI  - 77
IP  - 2
DP  - 2010 Jun 1
TI  - Outcomes of children with favorable histology wilms tumor and peritoneal implants 
      treated in National Wilms Tumor Studies-4 and -5.
PG  - 554-8
LID - 10.1016/j.ijrobp.2009.04.081 [doi]
AB  - PURPOSE: There are no published reports on the optimal management and survival 
      rates of children with Wilms tumor (WT) and peritoneal implants (PIs). METHODS 
      AND MATERIALS: Among favorable histology WT patients enrolled in the National 
      Wilms Tumor Study (NWTS)-4 and NWTS-5, 57 children had PIs at the time of 
      nephrectomy. The median age was 3 years 5 months (range, 3 months to 14 years). 
      The majority of children (42 of 57 [74%)] had Stage III tumors; 15 had Stage IV 
      disease. All patients received multimodality therapy. Of 56 children who 
      underwent primary surgery, 48 (84%) had gross total resection of all tumors. All 
      patients received 3-drug chemotherapy with vincristine, dactinomycin, and 
      doxorubicin. Whole-abdomen radiotherapy (RT) was used in 47 patients (82%), and 
      in 50 patients (88%) the RT dose was 10.5 Gy. RESULTS: After a median follow-up 
      of 7.5 years, the overall abdominal and systemic tumor control rates were 97% and 
      93%, respectively. A comparative analysis between children with PIs and those 
      without PIs showed no significant differences in the clinical characteristics 
      between the two groups. The 5-year event-free survival rates with and without PIs 
      were 90% (95% confidence interval, 78-96%) and 83% (95% confidence interval, 
      81-85%) respectively (p = 0.20). CONCLUSIONS: Multimodality therapy with surgery, 
      whole-abdomen RT, and three-drug chemotherapy delivered according to the NWTS-4 
      and -5 protocols resulted in excellent abdominal and systemic tumor control 
      rates. All children should be monitored in long-term surveillance programs for 
      the early detection and management of therapy-related toxicities.
CI  - Copyright 2010 Elsevier Inc. All rights reserved.
FAU - Kalapurakal, John A
AU  - Kalapurakal JA
AD  - Department of Radiation Oncology, Northwestern University, Chicago, IL, USA. 
      j-kalapurakal@northwestern.edu
FAU - Green, Daniel M
AU  - Green DM
FAU - Haase, Gerald
AU  - Haase G
FAU - Anderson, James R
AU  - Anderson JR
FAU - Dome, Jeffrey S
AU  - Dome JS
FAU - Grundy, Paul E
AU  - Grundy PE
LA  - eng
GR  - U10-CA-098543/CA/NCI NIH HHS/United States
GR  - U10 CA042326-15/CA/NCI NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - U10 CA098543-01/CA/NCI NIH HHS/United States
GR  - U10-CA-042326/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy/adverse effects/methods
MH  - Disease-Free Survival
MH  - Humans
MH  - Kidney Neoplasms/mortality/pathology/*therapy
MH  - Nephrectomy
MH  - Peritoneal Neoplasms/mortality/secondary/*therapy
MH  - Radiotherapy Dosage
MH  - Treatment Outcome
MH  - Wilms Tumor/mortality/secondary/*therapy
PMC - PMC2868597
MID - NIHMS117097
COIS- The authors have no conflict of interest to disclose.
EDAT- 2010/05/12 06:00
MHDA- 2010/05/25 06:00
PMCR- 2011/06/01
CRDT- 2010/05/12 06:00
PHST- 2009/01/27 00:00 [received]
PHST- 2009/04/22 00:00 [revised]
PHST- 2009/04/24 00:00 [accepted]
PHST- 2010/05/12 06:00 [entrez]
PHST- 2010/05/12 06:00 [pubmed]
PHST- 2010/05/25 06:00 [medline]
PHST- 2011/06/01 00:00 [pmc-release]
AID - S0360-3016(09)00725-1 [pii]
AID - 10.1016/j.ijrobp.2009.04.081 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):554-8. doi: 
      10.1016/j.ijrobp.2009.04.081.